35m
Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD Cowen Conf
Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several ...
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...
When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...
1d
How Amgen’s $4 Billion Long-Dated Bond Issuance At Amgen (AMGN) Has Changed Its Investment Story
On February 17, 2026, Amgen Inc. issued US$1.00 billion of 4.200% Senior Notes due 2031, US$1.75 billion of 4.850% Senior ...
Zacks Investment Research on MSN
Amgen Inc. (AMGN) is a trending stock: Facts to know before betting on it
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...
Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 ...
Amgen Inc. has reached a significant milestone as its stock hit an all-time high of 385.63 USD, with shares currently trading at $386.08, just shy of the 52-week high of $385.12. This achievement ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...
Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.
Compared to the aggregate P/E ratio of the 83.91 in the Biotechnology industry, Amgen Inc. has a lower P/E ratio of 26.69. Shareholders might be inclined to think that the stock might perform worse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results